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ABSTRACT:  Adverse  drug  reaction  (ADR)  is  poorly  reported  globally  but  more  in 
developing countries with poor participation by health professionals. Currently, there is no 
known literature on the Nigerian pharmacy students’ knowledge on ADR reporting. Hence 
the purpose of this study was to find out the level of knowledge of pharmacy students on 
the concept of pharmacovigilance and adverse drug reaction reporting and also to evaluate 
their  opinions  on  the  National  Pharmacovigilance  Centre  guidelines  on  adverse  drug 
reaction  reporting.  A  pretested  34-item  semi-structured  questionnaire  was  administered 
among  69  pharmacy  undergraduate  students  in  their  penultimate  and  final  years  that 
consented to take part in the study, in one of the universities in Nigeria. The study was 
carried out strictly adhering to the principles outlined in the Helsinki declaration of 1964, 
which was revised in 1975. The questionnaire used had four sections which included a 
section on biographical data, a section which evaluated the students knowledge on the 
concept of pharmacovigilance and adverse drug reaction reporting, a section on students 
personal experiences of adverse drug reactions and modes of reporting them and the final 
section  of  the  questionnaire  evaluated  the  students’  opinions  on  the  National 
Pharmacovigilance  Centre  guidelines  for  reporting  adverse  drug  reactions.  Descriptive 
statistics, Mann-Whitney U and Kruskal Wallis statistical tests were used to analyze the 
data obtained. None of the participants knew the sequence of reporting ADR. More than 
half,  40(58.0%)  had  heard  about  pharmacovigilance  at  symposiums,  7(10.1%)  during 
clinical clerkship program and 18(26.1%) from media jingles. Twenty nine (42.0%) agreed 
that pharmacovigilance was in their curriculum, however only 16(23.2%) could define the 
term correctly. None of the participants had seen or used an ADR form prior to the study, 
but the students could easily identify and describe the type of ADR they had personally 
experienced in detail, however, they did not know the channel of reporting it. Only 3% 
reported incidences of personal experience of ADR to the physician while another 3% 
reported cases of such to the pharmacist. There was a significant difference comparing 
students’ year of study in the pharmacy program with their opinion scores on the National 
Pharmacovigilance  Centre  (NPC)  guidelines  on  ADR  reporting  (p  <0.05).  The  lack  of 
pharmacovigilance and adverse drug reaction reporting courses in the pharmacy school 
curriculum result in the poor knowledge of the students on the concept of adverse drug 
reaction reporting, nonetheless the view and knowledge they had garnered from different 
sources helped the students in identifying and describing ADR but this is not enough in 
properly documenting cases of ADRs. Thus, the poor knowledge on ADR reporting among 
the  students  requires  speedy  implementation  of  new  curriculum  incorporating 
pharmacovigilance  to  enhance  the  involvement  of  pharmacists  in  ADR  reporting  in 
Nigeria. 
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INTRODUCTION 
 
Adverse  drug  reaction  (ADR)  is  defined  by  the 
World Health Organization (WHO) as a response 
to  a  drug  which  is  noxious  and  unintended,  and 
which  occurs  at  doses  normally  used  in  man  for 
prophylaxis, diagnosis, or therapy of disease or for 
the  modification  of  physiologic  function
1.  It  may 
result  from  the  irrational  use  of  medications
2-5 
leading to hospitalization and increased economic 
burden  to  individuals  and  nations
6.  Adverse  drug 
reaction has been shown to be the fourth to sixth 
principal  cause  of  mortality  in  industrialized 
nations
7.  Despite  this,  about  95%  incidences  of 
ADR  go  undocumented  worldwide
8,9.  However 
there is a dearth of information on ADR burden in 
developing countries like Nigeria
10. 
For the proper monitoring and reporting of ADR, 
various  countries  have  set  up  pharmacovigilance 
centres  responsible  for  the  monitoring  of  ADRs. 
The  Nigeria  National  Pharmacovigilance  Centre 
(NPC) established in 2004, is affiliated to the WHO 
international drug monitoring collaborating centre, 
Uppsala.  One  of  the  objectives  of  the  centre 
includes creating awareness among health workers 
of the need to consider ADR reporting as one of 
their responsibilities
10,11. 
Though,  the  Nigerian  NPC  guideline  requires  all 
health care workers including traditional medicine 
practitioners to report all suspected ADR, the few 
studies  carried  out  in  Nigeria  showed  that  health 
professionals were less involved in the reporting of 
ADR
10,12,13. In other studies, pharmacists have been 
shown to play important part in ADR reporting and 
other pharmacovigilance activities and were more 
likely  to  identify  ADRs  than  other  health  care 
workers in various practice settings
14-16. 
Oreagba  et  al
12  reported  lack  of  training  or 
inadequate training as one of the reasons adduced 
for  poor  knowledge  on  ADR  reporting  among 
community pharmacists in Nigeria. Another study 
in  Malaysia  showed  that  majority  of  final  year 
pharmacy  students  had  insufficient  knowledge 
about  pharmacovigilance  and  ADR  reporting
17. 
However, the involvements of pharmacy students 
in ADR reporting in some cases have contributed to 
increase in the number of documented ADRs
18.  
As intending practitioners, pharmacy students need 
to be well grounded in pharmacovigilance activity, 
ADR  reporting
15,18,19  and  be  familiar  with  their 
national  pharmacovigilance  centre  guidelines
20,21. 
Of the few studies conducted to evaluate students’ 
knowledge and attitude on ADR reporting, none, to 
the  best  of  our  knowledge  was  available  on 
Nigeria.  The  aim  of  this  study  was  therefore  to 
evaluate  pharmacy  students’  knowledge  of 
pharmacovigilance  and  ADR  reporting  and  to 
assess  their  opinions  on  the  NPC  guidelines  on 
ADR reporting. 
 
METHODOLOGY 
 
The  study  was  carried  out  in  September  2011 
among pharmacy students in one of the Nigerian 
Federal  Universities,  University  of  Ibadan.  
Participants were drawn from the penultimate and 
the final year classes. The study was conducted at 
the  end  of  the  second  semester  examinations  to 
ensure that all the students in their penultimate and 
final years had had all their lectures for the session 
signifying that the 400 level students (students in 
their  penultimate  year)  were  potential  final  year 
students  while  the  final  year  students  (500  level 
students) would soon graduate to be pharmacists. 
The study was carried out strictly adhering to the 
principles  outlined  in  the  Helsinki  declaration  of 
1964, which was revised in 1975. 
The  questionnaire,  which  was  the  data  collection 
instrument,  was  pre-tested  among  lower  level 
pharmacy  students  and  questions  like  religious 
affiliations  and  other  professional  qualifications 
were removed as suggested by the pharmacists in 
academia  (lecturers)  who  reviewed  the 
questionnaire. The results of the pre-test were not 
included in this study since the participants were 
not the primary targets of the study.  
The questionnaire had four sections which included 
sections  on  demographic  data,  open  and  close 
ended questions to assess the level of knowledge of 
the  student  on  pharmacovigilance  and  ADR 
reporting; a section on the personal experiences of 
the  student  with  ADR  and  how  it  was  reported 
while  the  last  section  was  on  ascertaining  the 
participants’  opinions  on  the  guidelines  for 
reporting ADRs by the NPC using a Likert scale 
with five graded responses ranging from strongly 
disagreed  to  strongly  agreed.  The  reliability  and 
internal  consistency  of  the  scales  based  on 
Cronbach  alpha  coefficient  was  between  0.7  and 
0.8 
The 87 students in the two classes were addressed 
separately on the study date and told the essence of 
the  study  and  participation  was  made  voluntary. 
Only 69 students who consented to take part in the 
study were given the questionnaires to fill.  
The  data  collected  were  summarized  with 
descriptive statistics: frequency and percentages, to 
evaluate  participants’  responses  while  Mann 
Whitney U and Kruskal Wallis tests were used to 
find the association between age, sex and year of 
study with the participants’ opinion scores on the 
National  Pharmacovigilance  Centre  adverse  drug 
reaction reporting guidelines. 
 
RESULT 
 
The mean age of the respondents was 23.42 ± 2.603 
(years ± SD). The response rate was 79.3% and the 
distribution  of  the  respondents’  age,  sex  and  the Showande et al / The concept of adverse drug reaction 
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year of study are shown in  Table 1.  Among  the 
students surveyed only 1 (1.4%) was married. 
 
Table  1:  Demographic  distribution  of 
participants 
 
 
All  the  participants  had  heard  of  the  term 
“pharmacovigilance” prior to the study but through 
informal  avenues  like  symposiums  40  (58.0%), 
student  organised  seminars,  20  (29.0%), 
professional  magazines  24  (34.8%),  internet  12 
(17.4%),  industrial  training  posting  9  (13.0%), 
clinical clerkship posting 7 (10.1%) and National 
Agency for Food Drug Administration and Control 
(NAFDAC)  media  jingles  18  (26.1%)  in  various 
combinations. Twenty-nine (42.0%) of the students 
reported  that  pharmacovigilance  and  ADR 
reporting was in their curriculum. When asked to 
define  pharmacovigilance  using  a  standard 
definition  such  as  that  of  the  World  Health 
Organization  (WHO),  16  (23.2%)  defined  it 
correctly, 20 (29.0%) gave wrong definitions while 
33 (47.8%) gave incomplete definitions. Some of 
the participants, 15 (21.7%), claimed to have seen 
the form used in reporting ADR, but when asked 
for  the  colour  of  the  form,  only  one  participant 
(6.7%) got the colour right. None of the respondent 
knew  what  the  sequence  of  reporting  ADR  was. 
Likewise,  no  participant  was  aware  of  the  WHO 
causality classification of ADR. 
Forty-one (59.4%) of the students who took part in 
the study had personally experienced ADR prior to 
the study. The ADRs experienced include urticaria 
16  (39.0%),  weakness  and  dizziness  4(9.8%), 
nausea and vomiting 3 (7.3%), syncope 2 (4.9%), 
hyperpigmentation  2  (4.9%),  severe  headache  2 
(4.9%),  others  include  dyskinesia  1  (2.4%), 
palpitation  1  (2.4%),  blurred  vision  1  (2.4%), 
“peeling of the skin” 1 (2.4%), insomnia 1 (2.4%), 
tremor 1 (2.4%), dysphagia 1 (2.4%), stomach ache 
1  (2.4%),  mouth  ulcer  1  (2.4%)  and  erythema 
multiforme 1 (2.4%). Some of the drugs that were 
implicated  in  these  ADRs  were:  chloroquine  12 
(29.3%),  sulphadoxine-pyrimethamine  7  (12.2%), 
artemether-lumefantrine 4 (9.8%), cotrimoxazole 3 
(7.3%), tramadol 2 (4.9%), and sulphamethoxazole 
2 (4.9%). Other drugs were: amoxicillin 1(2.4%), 
amodiaquine  1  (2.4%),  artesunate-amodiaquine  1 
(2.4%), propranolol 1 (2.4%), artesunate 1(2.4%), 
erythromycin 1 (2.4%), amoxicillin-clavulanic acid 
1  (2.4%),  diclofenac  1  (2.4%),  cyproheptadine  1 
(2.4%), ferrous gluconate 1 (2.4%), amodiaquine-
sulphadoxine-pyrimethamine  1  (2.4%), 
pyrimethamine-sulphametopyrazine  (Metakelfin®) 
1 (2.4%) and metronidazole 1 (2.4%). 
The onset of action of these ADRs as experienced 
by the students varied from immediately after the 
administration  of  the  drug,  less  than  an  hour,  1 
(2.4%);  to  few  hours  after  the  administration  of 
drug, less than 24 hours, 29 (70.7%) and days after 
the administration of the drug, more than a day, 11 
(26.8%). Twenty-three (56.1%) of those who had 
personally experienced a form of ADR prior to the 
study  reported  the  incidence  to  their  parents  17 
(73.9%), physicians 3 (13.0%) and pharmacists 3 
(13.0%). These ADRs were alleviated by stopping 
the intake of the medication in twelve (29.3%) of 
the  participants.  Sixteen  (39.1%)  took  another 
medication  for  the  relief  of  the  ADR,  while  11 
(26.8%) did not stop their medication but waited 
for  the  ADR  to  wear  off.  Other  respondents,  2 
(4.9%), could not remember what action they took. 
None of the ADRs experienced caused death but 5 
(12.2%)  of  those  who  experienced  ADR  were 
hospitalized as a result of the ADR. 
Though the participants in this study were unaware 
of  the  existence  of  national  pharmacovigilance 
center  guidelines  on  adverse  drug  reaction 
reporting, the final year students’ opinions agreed 
more with some of the guidelines such as nurses, 
traditional medicine practitioners or any health care 
worker  engaging  in  reporting  adverse  drug 
reactions  (Table  2).  However,  there  were 
significant  differences  in  the  association  of  the 
students’  year  of  study  with  the  participants’ 
opinion  scores  on  the  NPC  guidelines  on  ADR 
reporting (p<0.05) while there were no significant 
differences in the association of age and sex with 
the  participants’  opinion  scores  on  the  national 
pharmacovigilance  center  adverse  drug  reaction 
reporting guidelines p>0.05 (Table 3). 
Demographic 
variables 
Frequency 
distribution N (%) 
AGE  
≤ 22 years  33 (47.8%) 
23 – 24 years  18 (26.1%) 
≥ 25 years  18 (26.1%) 
SEX   
Male   33 (47.8%) 
Female   36 (52.2%) 
YEAR OF STUDY 
Fourth   45 (65.2%) 
Fifth   24 (34.8%) 
MARITAL STATUS 
Not married  68 (98.6%) 
Married   1 (1.4%) Showande et al / The concept of adverse drug reaction 
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Table 2: Participants’ opinions on some NPC ADR guidelines 
  Strongly 
disagree  
N (%) 
Disagree  
N (%) 
Undecided 
N (%) 
Agree  
N (%) 
Strongly 
agree  
N (%) 
Who should report ADR? 
Physicians  -  1 (1.4%)  1 (1.4%)  29 (42.0%)  38 (55.1%) 
Pharmacists  -  -  1 (1.4%)  8 (11.6%)  60 (87.0%) 
Dentists   3 (4.3%)  3 (4.3%)  18 (26.1%)  20 (29.0%)  25 (36.2%) 
Nurses  4 (5.8%)  5 (7.2%)  11 (15.9%)  25 (36.2%)  24 (34.8%) 
Traditional medicine practitioners  16 (23.2%)  6 (8.7%)  24 (34.8%)  9 (13.0%)  14 (20.3%) 
Any health provider  10 (14.5%)  5 (7.2%)  18 (26.1%)  13 (18.8%)  23 (33.3%) 
What are the basic principles of reporting ADR? 
Timeliness of reporting ADR  -  -  5 (7.2%)  23 (33.3%)  41 (59.4%) 
Reliability of suspect judgement  -  -  6 (8.7%)  22 (31.9%)  41 (59.4%) 
Completeness of report  -  -  3 (4.3%)  19 (27.5%)  47 (68.1%) 
Steps in assessing possible drug related ADR 
Medical and drug history should be taken  -  -  4 (5.8%)  29 (42.0%)  36 (52.2%) 
Other causes of ADR should be considered e.g. 
disease, food, herbs 
-  -  7 (10.1%)  24 (34.8%)  38 (35.1%) 
Drug  related  causes  should  be  considered  for 
ADR that is a new medical problem 
-  2 (2.9%)  8 (11.6%)  35 (50.7%)  24 (34.8%) 
Thorough  physical  and  medical  examinations 
should be carried out if necessary 
-  1 (1.4%)  3 (4.3%)  35 (50.7%)  30 (43.5%) 
Establishing onset of ADR is important  1 (1.4%)  1 (1.4%)  8 (11.6%)  27 (39.1%)  32 (46.4%) 
Determination of the effect of dechallenge and 
rechallenge 
1 (1.4%)  -  24 (34.8%)  28 (40.6%)  16 (23.2%) 
Cross checking the pharmacology of the drug  -  -  9 (13.0%)  31 (44.9%)  29 (42.0%) 
NPC – National Pharmacovigilance Centre, ADR – Adverse Drug Reaction 
 
Table 3: Association between demographic characteristics and participants’ opinion scores on some 
NPC ADR reporting guidelines  
Demographic variables  Total opinion scores for: 
Who should report ADR?  Principles of reporting ADR  Steps in assessing possible ADR 
N (Mean rank)  P  N (Mean rank)  P  N (Mean rank)  P 
AGE 
≤ 22 years  33 (34.80)  0.656
a  33 (35.97)  0.597
a  33 (36.22)  0.869
a 
23 – 24 years  18 (38.22)  18 (31.22)  18 (33.56) 
≥ 25 years  18 (32.14)  18 (37.00)  18 (34.03) 
SEX 
Male  33 (30.97)  0.108
b  33 (34.76)  0.918
b  33 (31.56)  0.170
b 
Female  36 (38.69)  36 (35.22)  36 (38.15) 
Year of study 
Fourth  45 (29.23)  0.01
b  45 (31.47)  0.031
b  45 (29.90)  0.004
b 
Fifth   24 (45.81)  24 (41.63)  24 (44.56) 
aKruskall Wallis test, 
bMann-Whitney U test, P < 0.05 was considered significant. NPC – National Pharmacovigilance Centre, 
ADR – Adverse Drug Reaction 
 
DISCUSSION 
 
Less than half of the participants in this study were 
not clearly sure if pharmacovigilance was one of 
the courses listed in their curriculum, showing that 
the students were not familiar with the contents of 
their  curriculum.  The  current  course  outline,  as 
listed by the Pharmacists Council of Nigeria (PCN) 
which  is  the  regulatory  body  for  pharmacy 
education and practice in Nigeria, did not contain 
pharmacovigilance  as  a  course
22.  In  addition,  the 
University  students’  prospectus  handbook  which 
lists  the  course  outlines  at  various  stages  of  the 
undergraduate  study  did  not  contain 
pharmacovigilance or ADR reporting as a topic
23. 
These may explain why the course was not taught 
to  the  students.  Furthermore,  the  participants  had 
heard about pharmacovigilance and ADR reporting 
through informal means like seminars, professional 
magazines,  and  during  clerkship  training  but  not 
through  formal  classroom  lectures.  At  a 
stakeholders  meeting  in  2008  between  pharmacy Showande et al / The concept of adverse drug reaction 
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professionals and the representative of the Minister 
of  Health  in  Nigeria,  the  Doctor  of  Pharmacy 
(Pharm. D) programme for pharmacy students was 
adopted. New courses including pharmacovigilance 
were to be introduced
24, but up till the time of this 
study  the  new  curriculum  had  not  been 
implemented in twelve out of the thirteen pharmacy 
schools in the country. Nigerian pharmacy students 
are  not  the  only  one  not  well  trained  in  ADR 
reporting. A study showed that the medical school 
curriculum  was  lacking  in  pharmacovigilance 
courses
25. 
Students  in  the  fourth  and  final  years  showed 
deficiency  in  knowledge  on  pharmacovigilance 
activities since only one quarter of the participants 
could  define  pharmacovigilance  correctly 
according  to  the  World  Health  Organisation 
definition
1,26. None of the participants in the study 
had used a copy of the ADR-reporting form prior to 
the study. All the participants agreed that they do 
not  know  how  to  go  about  processing  and 
documenting  ADR  report.  This  lack  of  adequate 
knowledge could translate to inadequate or lack of 
participation  of  these  students  in  reporting  ADR 
when  they  eventually  become  pharmacists.  This 
may be one of the reasons why a study conducted 
among community pharmacists in Lagos, Nigeria, 
on  knowledge  and  attitude  to  ADR  reporting 
showed  poor  knowledge  and  participation  in 
pharmacovigilance  activities
12.  Nonetheless,  poor 
knowledge  in  pharmacovigilance  activities  is  not 
restricted  to  pharmacists  and  pharmacy  students, 
medical  students  and  physicians  also  showed  the 
same  trend  as  reported  by  Okezie  & 
Olufunmilayo
13  where  less  than  one  third  of  the 
physicians surveyed in a city in Nigeria had ever 
reported an ADR. Ohaju-Obodo & Iribhogbe
27 also 
observed that more than three-quarters of resident 
doctors  in  another  major  city  in  Nigeria  had 
inadequate  knowledge  about  pharmacovigilance. 
Another survey among medical students in France 
showed  that  majority  lacked  knowledge  of 
pharmacovigilance
28  and  in  a  northern  Italian 
district it was observed that physicians have little 
knowledge on ADRs and their reporting systems
29. 
The  reasons  given  were  lack  of  knowledge  that 
ADR reporting forms were available and ignorance 
of the reporting procedure.  
A deficiency in ADR reporting is poor-reporting
30 
even  though  this  is  a  worldwide  phenomenon; 
ADRs are much more under-reported in Nigeria
31. 
This stems from lack of knowledge of professionals 
on pharmacovigilance activities and ADR reporting 
procedures as evidenced by various studies
12,13,27,31, 
and  also  noticed  in  the  present  study.  Between 
2004 and 2008 only 672 cases of ADR had been 
reported in Nigeria
32, a country with a population 
of 150 million.  
Participants  who  had  reported  personally 
experienced ADRs to pharmacists and physicians 
were  grossly  low.  This  may  be  due  to  lack  of 
awareness about the appropriate persons to report 
ADR to. The students showed good familiarity with 
what an ADR is. They easily described the types of 
ADR  they  had  experienced  and  were  able  to 
identify  the  medications  responsible.  They  were 
also able to identify the onset of the ADR and what 
was  done  to  alleviate  or  stop  the  ADR.  These 
knowledge are partly needed in conducting detail 
ADR reporting, however, the participants could not 
utilize  this  knowledge  to  conduct  proper  ADR 
report since it was not part of their curriculum. As 
stated  by  Nwokike
10  in  his  study  that  attention 
should shift from spontaneous reporting by health 
care  workers  to  self-report  or  patient  initiated 
reporting of ADRs; encouraging pharmacy students 
to self report incidences of personal experiences of 
ADR  may  motivate  them  into  engaging  in 
pharmacovigilance activities after graduation. 
Probably based on the little knowledge the students 
had  acquired  from  various  sources  on 
pharmacovigilance  activities  and  related  courses, 
the  final  year  students’  opinions  on  the  national 
pharmacovigilance  centre  guidelines  on  adverse 
drug  reaction  reporting  agreed  more  with  some 
contents  of  the  guidelines,  though  they  were  not 
aware of the existence of such guidelines prior to 
the study but were slightly more informed than the 
participants in the penultimate year.  
 
CONCLUSION 
 
Non  inclusion  of  pharmacovigilance  and  ADR 
reporting in the pharmacy curriculum is probably 
ascribed  with  deficiency  in  knowledge  of 
undergraduate  pharmacy  students  in  Nigeria  on 
ADR  reporting  and  other  pharmacovigilance 
activities.  As  future  pharmacy  practitioners, 
pharmacy  students  need  to  be  well  grounded  in 
pharmacovigilance  activities  to  reduce  the 
incidence  of  ADR  under-reporting.  Pharmacists 
Council  of  Nigerian  in  conjunction  with  the 
Nigerian University Commission should ensure the 
speedy  implementation  of  the  new  curriculum 
which includes courses like pharmacovigilance to 
equip  and  encourage  future  participation  of 
pharmacists in pharmacovigilance activities. 
 
ACKNOWLEDGEMENT 
 
The  authors  wish  to  thank  the  students  who 
participated in this study. 
 
REFERENCES 
 
1.  Requirements  for  adverse  reaction  reporting. 
Geneva,  Switzerland:  World  Health 
Organization. 1975. 
2.  Pouyanne  P,  Haramburu  F,  Imbs  JL,  et  al. 
Admissions to hospital caused by adverse drug Showande et al / The concept of adverse drug reaction 
	 ﾠ
Copyrighted © by Dr. Arun Kumar Agnihotri. All rights reserved 
 
29	 ﾠ
reactions:  cross-sectional  incidence  study. 
French Pharmacovigilance Centres. Br Med J. 
2000;320(7241):1036. 
3.  Hallas  J,  Harvard  B,  Gram  LF,  et  al.  Drug 
related  hospital  admissions:  the  role  of 
definitions and intensity of data collection and 
possibility  of  prevention.  J  Intern  Med. 
1990;228(2):83-90. 
4.  Odusanya  OO,  Oyediran  MA.  Rational  drug 
use at the primary health care centres in Lagos, 
Nigeria.  Nigerian  Quart  J  Hosp  Med. 
2000;10:4-7. 
5.  Akinyede  AA,  Mabadeje  AFB,  Aliu  MO.  A 
comparative  study  of  patterns  of  prescription 
of antibiotics in two health centres in Lagos. J 
Nig Infect Cont Assoc. 2000;3:20-3. 
6.  Lundkvist  J,  Jönsson  B.  Pharmacoeconomics 
of  adverse  drug  reactions.  Fundam  Clin 
Pharmacol. 2004;18(3):275-80. 
7.  Lazarou J, Pomeranz BH, Corey PN. Incidence 
of  adverse  drug  reactions  in  hospitalized 
patients:  a  meta-analysis  of  prospective 
studies. JAMA. 1998;279(15):1200-5. 
8.  Institute of Medicine (US). To err is human: 
Building  a  Safer  health  system.  Kohn  LT, 
Corrigan  JM,  Donaldson  MS,  eds. 
Washington:  The  Institute;  2000. 
(http://www.nap.edu/books/0309068371/html/ 
- accessed on December 4th 2011) 
9.  Fletcher  AP.  Spontaneous  adverse  drug 
reporting  versus  event  monitoring:  a 
comparison. J R Soc Med. 1991; 84:341-4. 
10.  Nwokike  J.  Monitoring  Adverse  Drug 
Reaction  in  the  public  health  programs:  the 
case  of  the  Nigeria  TB  program.  2008. 
(Available  at 
www.www.apps.who.int/medicinedocs/docum
ents/s18400en/s18400en.pdf  accessed  12th 
December, 2011) 
11.  National Pharmacovigilance centre, NAFDAC, 
Nigeria.  Safety  of  medicines  in  Nigeria:  A 
guide for detecting and reporting adverse drug 
reactions – why health professionals must act. 
(http://www.nafdacnigeria.org/pharmacovigila
nce.html - accessed on 15th December, 2011) 
12.  Oreagba  A,  Ogunleye  OJ,  Olayemi  SO.  The 
knowledge,  perceptions  and  practice  of 
pharmacovigilance  amongst  community 
pharmacists in Lagos state, south west Nigeria. 
Pharmacoepidemiol Drug Saf. 2011;20(1):30-
5.  
13.  Okezie  EO,  Olufunmilayo  F.  Adverse  drug 
reactions  reporting  by  physicians  in  Ibadan, 
Nigeria.  Pharmacoepidemiol  Drug  Saf. 
2008;17(5):517-22 
14.  Thompson  A,  Osgood  T,  Ragucci  K.  Patient 
care interventions by pharmacy students in the 
intensive care unit. Am J Health Syst Pharm. 
2007;64(17):1788-9. 
15.  Sears E, Generali J. Adverse drug reaction and 
medication  error  reporting  by  pharmacy 
students.  Ann  Pharmacotherapy. 
2005;39(3):452-9. 
16.  van Grootheest AC, de Jong-van den Berg LT. 
The  role  of  hospital  and  community 
pharmacists in pharmacovigilance. Res Social 
Adm Pharm. 2005;1(1):126-33. 
17.  Elkalmi  RM,  Hassali  MA,  Izham  MI,  et  al. 
Pharmacy students’ knowledge and perception 
about pharmacovigilance in Malaysian public 
universities. Am J Pharm Educ. 2011;75(5):96. 
18.  Birdwell SW, Sullivan DL, Grauer DW, et al. 
Pharmacy students’ knowledge of medication-
error  reporting.  Am  J  Health  Syst  Pharm. 
2003;60(10):1054-5. 
19.  Sullivan  KM,  Spooner  LM.  Adverse-drug-
reaction reporting by pharmacy students in a 
teaching  hospital.  Am  J  Health  Syst  Pharm. 
2008;65(12):1177-9 
20.  Vallano  A,  Cereza  G,  Pedros  C,  et  al. 
Obstacles  and  solutions  for  spontaneous 
reporting  of  adverse  drug  reactions  in  the 
hospital.  Br  J  Clin  Pharmacol. 
2005;60(6):653-8. 
21.  Backstrom  M,  Mjorndal  T,  Dahlqvist  R. 
Under-reporting  of  serious  adverse  drug 
reactions  in  Sweden.  Pharmacoepidemiol 
Drug Saf. 2004;13(7):483-7. 
22.  Pharmacists  Council  of  Nigeria.  Benchmark 
and  Minimum  Academic  Standard  – 
Pharmaceutical  Sciences. 
(http://www.pcnng.org/Benchmark%20and%2
0Minimum%20Academic%20Standard-
Pharmaceutical%20Sciences.pdf – accessed on 
December 15th 2011) 
23.  Faculty  of  pharmacy,  University  of  Ibadan 
Prospectus  2004-2006.  1st  ed.  Publisher: 
Faculty  of  Ibadan,  University  of  Ibadan. 
Nigeria. 
24.  Stakeholders meet on Pharm D programme.  A 
publication  of  the  office  of  the  executive 
secretary  19th February 2007;2(8): (available 
online  at 
http://www.nuc.edu.ng/Bulletins/Monday%20
Bulletin%20of%2019%20FEBRARY%202007
.pdf Accessed on 30th January, 2012) 
25.  Shankar P, Subish P, Mishra P, et al. Teaching 
pharmacovigilance  to  medical  students  and 
doctors. Indian J Pharmacol. 2006;38:316-9. 
26.  Safety  Monitoring  of  Medicinal  Products: 
Guidelines  for  Setting  Up  and  Running  a 
Pharmacovigilance  Centre.  WHO  2000,  The 
Uppsala  Monitoring  centre.  (available  at 
http://apps.who.int/medicinedocs/en/d/Jh2934e
/3.html - accessed on December 15th 2011) 
27.  Ohaju-Obodo  JO,    Iribhogbe  OI.  Extent  of 
pharmacovigilance among resident doctors in 
Edo  and  Lagos  states  of  Nigeria. Showande et al / The concept of adverse drug reaction 
	 ﾠ
Copyrighted © by Dr. Arun Kumar Agnihotri. All rights reserved 
 
30	 ﾠ
Pharmacoepidemiol  Drug  Saf. 
2009;19(2):191-5. 
28.  Graille V, Lapeyre-Mestre M, Montastruc JL. 
Drug  vigilance:  opinion  survey  among 
residents  of  a  university  hospital.  Therapie. 
1994;49(5):451-4   
29.  Cosentino M, Leoni O, Banfi F, et al. Attitudes 
to adverse drug reaction reporting by medical 
practitioners  in  a  Northern  Italian  district. 
Pharmacol Res 1997;35(2):85-8.     
30.  Wiholm  BE,  Olsson  S,  Moore  N,  et  al. 
Spontaneous  reporting  systems  outside  the 
United  States.  In  StromBL  (eds). 
Pharmacoepidemiology.  John  Wiley  &  Sons 
Ltd: Chichester. 1994;139-55. 
31.  Oshikoya  KA,  Njokanma  OF,  Chukwuwura 
HA, et al. Adverse drug reactions in Nigerian 
Children.  Paed  Perinat  Drug  Ther. 
2007;8(2):81-8. 
32.  WHO Report of follow-up consultants' training 
course on pharmacovigilance.  Accra 16 - 19 
June,  2008.  (available  online  at 
www.who.int/medicines/areas/quality_safety/s
afety_efficacy/ghanareportofconsultants.pdf 
accessed on 30th January, 2012). 
 